[1] HAO Xuan ZHANG Junru,.Theoretical Discussion on Prevention and Treatment of H-type Hypertension with Traditional Chinese Medicine Based on Intestinal Flora [J]. Modern Traditional Chinese Medicine, 2022, 1(05): 81-88. [doi: 10.13424/j.cnki.mtcm.2022.05.016]
Theoretical Discussion on Prevention and Treatment
of H-type Hypertension with Traditional Chinese Medicine
Based on Intestinal Flora
- Article number:
- 1672-0571(2022)05-0081-08
- Keywords:
- Key words:Intestinal flora; H-type hypertension; Homocysteine; Chinese medicine; Compound preparation
- ZTFLH:
- R259
- Code:
- A
- Abstract:
- Abstract：Gut microbiota (GM)，as an important part of human micro ecosystem，plays an important role in nutritional metabolism and immune regulation，directly or indirectly affecting human health.Through a number of clinical studies and the application of gene sequencing technology，it was found that the diversity and structural changes of intestinal flora were closely related to hypertension.Hypertension has a high incidence rate in incidence rate，with a high mortality and disability rate of complications.H-type hypertension accounts for 75% of primary hypertension in China，so the treatment of H-type hypertension is the key to improve the control rate of hypertension in China.The study found that traditional Chinese medicine has unique advantages in regulating intestinal flora by protecting intestinal probiotics，increasing the richness of flora，inhibiting the growth of harmful bacteria，and regulating intestinal flora.This paper reviews the effect of traditional Chinese medicine in improving intestinal flora on H-type hypertension in recent years，and provides theoretical ideas for the prevention and treatment of H-type hypertension with traditional Chinese medicine.
References:
[1]中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[2]Qin XH,Huo Y.H-Type hypertension,stroke and diabetes in China:Opportunities for primary prevention[J].Journal of Diabetes,2016,8(1):38-40.
[3]Song QQ,Wang YK,Huang LX,et al.Review of the relationships among polysaccharides,gut microbiota,and human health[J].Food Research International,2021（140）:109858.
[4]Li J,Yang XC,Zhou X,et al.The role and mechanism of intestinal flora in blood pressure regulation and hypertension development[J].Antioxidants & Redox Signaling,2021,34(10):811-830.
[5]阮秋红,郑燕慧,陈晓军,等.H型高血压的中医研究进展[J].中外医学研究,2019,17(35):181-183.
[6]李建平,卢新政,霍勇,等.H型高血压诊断与治疗专家共识[J].中华高血压杂志,2016,24(2):123-127.
[7]刘力生.中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-743.
[8]Zaric BL,Obradovic M,Bajic V,et al.Homocysteine and hyperhomocysteinaemia[J].Current Medicinal Chemistry,2019,26(16):2948-2961.
[9]Tyagi SC,Lominadze D,Roberts AM.Homocysteine in microvascular endothelial cell barrier permeability[J].Cell Biochemistry and Biophysics,2005,43(1):37-44.
[10]Fu Y,Wang X,Kong W.Hyperhomocysteinaemia and vascular injury:advances in mechanisms and drug targets[J].British Journal of Pharmacology,2018,175(8):1173-1189.
[11]李忆,张艳宁.同型半胱氨酸在慢性肾脏病心血管疾病发生发展中研究进展[J].中国现代医生,2020,58(22):186-192.
[12]Eckburg PB,Bik EM,Bernstein CN,et al.Diversity of the human intestinal microbial flora[J].Science,2005,308(5728):1635-1638.
[13]Sanz Y,A Moya-Pérez.Microbiota,Inflammation and Obesity[J].Advances in Experimental Medicine and Biology,2014（817）:291-317.
[14]Biesalski HK.Nutrition meets the microbiome:micronutrients and the microbiota[J].Annals of the New York Academy of Sciences,2016,1372(1):53-64.
[15]李雄彪,马庆英,崔云龙.丁酸和叶酸预防与治疗肠道疾病及其分子基础[J].世界华人消化杂志,2006,14(32):3071-3080.
[16]Yoshii K,Hosomi K,Sawane K,et al.Metabolism of dietary and microbial vitamin B family in the regulation of host immunity[J].Frontiers in Nutrition,2019,6:48.
[17]Degnan PH,Taga ME,Goodman AL.Vitamin B12 as a modulator of gut microbial ecology[J].Cell Metabolism,2014,20(5):769-778.
[18]Biesalski HK.Nutrition meets the microbiome:micronutrients and the microbiota[J].Annals of the New York Academy of Sciences,2016,1372(1):53-64.
[19]Cani PD.Human gut microbiome:hopes,threats and promises[J].Gut,2018,67(9):1716-1725.
[20]Pluznick JL.Microbial short-chain fatty acids and blood pressure regulation[J].Current Hypertension Reports,2017,19(4):25.
[21]Yang F,Chen HW,Gao YH,et al.Gut microbiota-derived short-chain fatty acids and hypertension:Mechanism and treatment[J].Biomedicine & Pharmacotherapy,2020（130）:110503.
[22]Ufnal M,Jazwiec R,Dadlez M,et al.Trimethylamine-N-oxide:a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats[J].Canadian Journal of Cardiology,2014,30(12):1700-1705.
[23]叶澍承,杨宁,杨国红,等.肠道菌群参与高血压形成的机制[J].医学综述,2018,24(22):4390-4394.
[24]王洁,高静.新型生物标志物TMAO与心血管疾病关系的研究进展[J].天津医药,2020,48(12):1244-1248.
[25]Adnan S,Nelson JW,Ajami NJ,et al.Alterations in the gut microbiota can elicit hypertension in rats[J].Physiological Genomics,2017,49(2):96-104.
[26]Yang T,Santisteban MM,Rodriguez V,et al.Gut dysbiosis is linked to hypertension[J].Hypertension,2015,65(6):1331-1340.
[27]Liu JL,An N,Ma C,et al.Correlation analysis of intestinal flora with hypertension[J].Experimental and Therapeutic Medicine,2018,16(3):2325-2330.
[28]Li J,Zhao FQ,Wang YD,et al.Gut microbiota dysbiosis contributes to the development of hypertension[J].Microbiome,2017,5(1):1-19.
[29]解天骁,赵倩倩,王忆勤,等.H型高血压中医证型分布及其与临床检测指标的相关性研究进展[J].中西医结合心脑血管病杂志,2020,18(23):3968-3971.
[30]庄微,孔娜娜,刘挺松,等.H型高血压中医证型分布特点[J].中国误诊学杂志,2020,15(5):196-198.
[31]韩聪,姜月华,李伟,等.基于16S rDNA测序技术探索黄芪-丹参药对干预自发性高血压大鼠肠道菌群的机制[J].中华中医药杂志,2019,34(5):2233-2237.
[32]韩聪,周乐,姜月华,等.基于代谢组学探讨黄芪-丹参药对的降压机制[J].中华中医药杂志,2020,35(9):4352-4356.
[33]项广宇.注射用丹参多酚酸对缺血性脑卒中患者同型半胱氨酸、D-二聚体、高敏C-反应蛋白水平和血液流变参数的影响[J].药物评价研究,2019,42(2):291-295.
[34]李忆凡.黄芪注射液对妊娠期高血压疾病患者血压及血清Hcy、CysC水平的影响[J].微量元素与健康研究,2019,36(3):39-40.
[35]王丽丽,袁从英.硝苯地平联合黄芪注射液对妊娠期高血压疾病患者同型半胱氨酸和胱抑素水平的影响[J].中国妇幼保健,2016,31(18):3698-3700.
[36]陈明亮.白藜芦醇通过重塑肠道菌群改善动脉粥样硬化的作用及机制研究[D].重庆:第三军医大学,2016.
[37]任亚浩,李翠,赵越,等.白藜芦醇对衰老小鼠氧化应激和血清同型半胱氨酸的影响[J].实用预防医学,2017,24(10):1172-1174.
[38]周志宏,张福伟,熊槟洋,等.白藜芦醇对自发性高血压大鼠主动脉重塑的影响及机制探讨[J].临床和实验医学杂志,2018,17(19):2029-2033.
[39]亓英姿,姜月华,姜凌宇,等.杜仲-刺蒺藜对老龄自发性高血压大鼠肠道微生物组的影响[J].中华高血压杂志,2019,27(5):454-462.
[40]吴东儿,卞筱泓,许激扬,等.松脂醇二葡萄糖苷对ECV-304细胞损伤的保护作用和CAV-1表达的影响[J].药物生物技术,2014,21(3):218-221.
[41]Phillips OA,Mathew KT,Oriowo MA.Antihypertensive and vasodilator effects of methanolic and aqueous extracts of Tribulus terrestris in rats[J].Journal of Ethnopharmacology,2006,104(3):351-355.
[42]叶泉英,陈启生,李艳文,等.决明子水提物干预N-硝基-L-精氨酸甲酯诱导高血压模型大鼠血压的变化[J].中国组织工程研究,2021,25(11):1705-1711.
[43]Sung BK,Kim MK,Lee WH,et al.Growth responses of Cassia obtusifolia toward human intestinal bacteria[J].Fitoterapia,2004,75(5):505-509.
[44]孙岚萍,顾志荣,马转霞,等.基于数据挖掘技术研究中医药治疗高同型半胱氨酸血症的组方配伍规律[J].中草药,2020,51(18):4712-4718.
[45]周晨,王守富,刘萧萧.中医药治疗H型高血压临床研究进展[J].中医研究,2019,32(5):78-80.
[46]房景梅,王启隆,李琳.肠道菌群与血管疾病的相关性及中药干预研究进展[J].世界科学技术-中医药现代化,2019,21(6):1127-1134.
[47]周俊怡,周严严,赵海誉,等.黄连解毒汤对健康大鼠肠道菌群结构影响的研究[J].浙江中医药大学学报,2018,42(10):804-809.
[48]徐君.黄芩—黄连药对与肠道菌群的相互作用研究[D].南京:南京中医药大学,2014.
[49]张志伟,岳桂华,张爱珍.黄连解毒汤对自发性高血压大鼠血压和炎症因子的影响[J].中华中医药杂志,2011,26(7):1627-1629.
[50]马晓聪,熊兴江,蔡涛,等.黄连解毒汤对自发性高血压大鼠主动脉组织miR-133a/Caveolin-1/eNOS通路调控作用机制的研究[J].中华中医药杂志,2020,35(8):3868-3872.
[51]吴宏华,周先富.H型高血压患者采用半夏白术天麻汤加减综合治疗对改善血压及血浆Hcy的影响[J].中华中医药学刊,2016,34(9):2295-2297.
[52]周倩仪,马楷奇,郭意欣,等.天麻钩藤饮联用血管紧张素转化酶抑制剂治疗原发性高血压的Meta分析[J].中国实验方剂学杂志,2015,21(4):206-212.
[53]袁晶,焦福智,刘欣,等.天麻钩藤饮治疗H型高血压的Meta分析[J].世界中医药,2021,16(14):2129-2137.
[54]华中一,李洪梅,孙建辉,等.鲜天麻提取物对小鼠肠道菌群结构的影响[J].中国中药杂志,2019,44(5):1004-1009.
Memo
基金项目：国家中医药管理局-中医药传统知识收集整理项目（141020001）；陕西省中医药管理局资助项目（2021-ZZ-JC036）;陕西省科技厅项目2022JM-473）